BR112022024262A2 - Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april - Google Patents
Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a aprilInfo
- Publication number
- BR112022024262A2 BR112022024262A2 BR112022024262A BR112022024262A BR112022024262A2 BR 112022024262 A2 BR112022024262 A2 BR 112022024262A2 BR 112022024262 A BR112022024262 A BR 112022024262A BR 112022024262 A BR112022024262 A BR 112022024262A BR 112022024262 A2 BR112022024262 A2 BR 112022024262A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- april
- methods
- iga nephropathy
- binding antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062704831P | 2020-05-29 | 2020-05-29 | |
| PCT/US2021/035011 WO2021243298A1 (en) | 2020-05-29 | 2021-05-28 | Methods of treating iga nephropathy with an april binding antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022024262A2 true BR112022024262A2 (pt) | 2023-02-23 |
Family
ID=78722933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022024262A BR112022024262A2 (pt) | 2020-05-29 | 2021-05-28 | Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210379183A1 (enExample) |
| EP (1) | EP4157339A4 (enExample) |
| JP (2) | JP7843248B2 (enExample) |
| KR (1) | KR20230017223A (enExample) |
| CN (1) | CN115996748A (enExample) |
| AU (1) | AU2021279035A1 (enExample) |
| BR (1) | BR112022024262A2 (enExample) |
| CA (1) | CA3179812A1 (enExample) |
| IL (1) | IL298370A (enExample) |
| MX (1) | MX2022014995A (enExample) |
| WO (1) | WO2021243298A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| CN116322775A (zh) | 2020-06-02 | 2023-06-23 | 阿雷斯贸易股份有限公司 | IgA肾病治疗的相关方法 |
| AU2023262513A1 (en) | 2022-04-25 | 2024-12-05 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| AU2023366516A1 (en) | 2022-10-28 | 2025-05-15 | Aduro Biotech Holdings, Europe B.V. | Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody |
| WO2024099272A1 (zh) * | 2022-11-07 | 2024-05-16 | 信瑞诺医药（上海）有限公司 | 用于治疗IgA肾病的内皮素受体拮抗剂和糖皮质激素的组合 |
| WO2026050274A2 (en) * | 2024-08-27 | 2026-03-05 | Paragon Therapeutics, Inc. | April binding proteins, compositions, and methods of use thereof |
| WO2026067804A1 (zh) * | 2024-09-30 | 2026-04-02 | 信立泰(成都)生物技术有限公司 | 一种抗april抗体或其抗原结合片段及用途 |
| WO2026122561A2 (en) | 2024-12-03 | 2026-06-11 | Otsuka America Pharmaceutical, Inc. | Methods of treating sjögren's disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA74798C2 (uk) * | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| PT1610820E (pt) * | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| KR20080074120A (ko) * | 2005-10-13 | 2008-08-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물 |
| CA2681728C (en) * | 2007-03-27 | 2015-12-22 | Zymogenetics, Inc. | Combination of blys and/or april inhibition and immunnosuppressants for treatment of autoimmune disease |
| RU2481824C2 (ru) * | 2008-10-29 | 2013-05-20 | Аблинкс Н.В | Препараты однодоменных антигенсвязывающих молекул |
| WO2010100056A2 (en) * | 2009-03-02 | 2010-09-10 | Stichting Top Institute Pharma | Antibodies against a proliferating inducing ligand (april) |
| SG184355A1 (en) * | 2010-03-01 | 2012-11-29 | Progenics Pharm Inc | Concentrated protein formulations and uses thereof |
| US8613919B1 (en) * | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| KR20180066241A (ko) * | 2015-10-28 | 2018-06-18 | 아두로 바이오테크, 인코포레이티드 | “인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법 |
| JOP20170017B1 (ar) * | 2016-01-25 | 2021-08-17 | Amgen Res Munich Gmbh | تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص |
| US12103979B2 (en) * | 2017-04-28 | 2024-10-01 | Amgen Inc. | N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| US11034768B2 (en) * | 2017-10-30 | 2021-06-15 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
| CN110464842B (zh) * | 2018-05-11 | 2022-10-14 | 信达生物制药(苏州)有限公司 | 包含抗pcsk9抗体的制剂及其用途 |
-
2021
- 2021-05-28 AU AU2021279035A patent/AU2021279035A1/en active Pending
- 2021-05-28 US US17/334,590 patent/US20210379183A1/en active Pending
- 2021-05-28 JP JP2022573609A patent/JP7843248B2/ja active Active
- 2021-05-28 CA CA3179812A patent/CA3179812A1/en active Pending
- 2021-05-28 BR BR112022024262A patent/BR112022024262A2/pt unknown
- 2021-05-28 MX MX2022014995A patent/MX2022014995A/es unknown
- 2021-05-28 EP EP21813022.7A patent/EP4157339A4/en active Pending
- 2021-05-28 WO PCT/US2021/035011 patent/WO2021243298A1/en not_active Ceased
- 2021-05-28 KR KR1020227043773A patent/KR20230017223A/ko active Pending
- 2021-05-28 CN CN202180046732.2A patent/CN115996748A/zh active Pending
- 2021-05-28 IL IL298370A patent/IL298370A/en unknown
-
2026
- 2026-03-30 JP JP2026056121A patent/JP2026126199A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021243298A1 (en) | 2021-12-02 |
| MX2022014995A (es) | 2023-02-09 |
| JP2023527563A (ja) | 2023-06-29 |
| EP4157339A1 (en) | 2023-04-05 |
| US20210379183A1 (en) | 2021-12-09 |
| CA3179812A1 (en) | 2021-12-02 |
| EP4157339A4 (en) | 2024-08-07 |
| JP2026126199A (ja) | 2026-08-04 |
| JP7843248B2 (ja) | 2026-04-09 |
| IL298370A (en) | 2023-01-01 |
| AU2021279035A1 (en) | 2023-02-02 |
| KR20230017223A (ko) | 2023-02-03 |
| CN115996748A (zh) | 2023-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020001974A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093) | |
| CL2024002250A1 (es) | Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria. | |
| BR112022017930A2 (pt) | Anticorpos anticoronavírus e métodos de uso | |
| BR112021008873A8 (pt) | Formulação | |
| AR101846A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| BR112022023088A2 (pt) | Anticorpos contra sars-cov-2 e métodos de seleção e uso dos mesmos | |
| MX393951B (es) | Anticuerpos antisortilina y métodos para su uso. | |
| PE20181151A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| ECSP21022299A (es) | Anticuerpos de anti-cd33 y métodos para usarlos | |
| UY36942A (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
| NI201000028A (es) | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso. | |
| MX2022014995A (es) | Metodos de tratamiento de la nefropatia por iga con un anticuerpo de union a april. | |
| MX2020013428A (es) | Anticuerpos monoclonales contra inmunoglobulina de celulas t y molecula que contiene dominio de mucina-3 (tim-3) humana. | |
| MX2021015156A (es) | Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos. | |
| BR112019004990A2 (pt) | anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo | |
| BR112021021281A2 (pt) | Anticorpo monoclonal que se liga especificamente ao gitr | |
| CR20220329A (es) | Anticuerpos anti–mertk y metodos de uso de los mismos | |
| BR112022013494A2 (pt) | Anticorpo anti-galectina-9 e usos do mesmo | |
| ECSP22056627A (es) | Anticuerpos contra la integrina alfa 11 beta 1 | |
| BR112021016596A2 (pt) | Anticorpo anti-pd-l1 e uso do mesmo | |
| CO2022019225A2 (es) | Anticuerpos anti-hbv y métodos de uso | |
| MX2024015304A (es) | Terapias combinadas con un anticuerpo antifactor xi/factor xia | |
| BR112021012022A2 (pt) | Anticorpo que se liga ao vegf e à il-1beta e métodos de uso | |
| BR112021021077A2 (pt) | Métodos de diagnóstico e tratamento de artrite reumatoide | |
| BR112021020612A2 (pt) | Métodos para tratamento de sujeitos com artrite psoriática |